A young child, Oli-Jay Morris, has recently received a diagnosis of a highly uncommon medical condition that doctors have never encountered before. Oli-Jay is suffering from mitochondrial disease DNM1L-EMPF, a severe illness caused by mutations in the DNM1L gene leading to significant neurological and metabolic issues. The EMPF variant of the disease affecting Oli-Jay is entirely unique to him.
Mitochondrial disease hampers the body’s ability to generate the necessary energy for basic bodily functions like eating, speaking, crying, and breathing, leaving Oli-Jay critically ill. Despite the grim situation, there is a glimmer of hope for his family in their quest for treatment.
Following the diagnosis, Oli-Jay’s father, Rob, reached out to the DNM1L Foundation in the United States, which facilitated a meeting with Unravel Biosciences. This company conducted a thorough genetic analysis of Oli-Jay’s condition and identified potential drugs that could enhance his quality of life, some of which are not currently available through the NHS.
To cover the costs of the analysis, Oli-Jay’s family from Haverhill, Suffolk, raised £14,000 and recently received the comprehensive report. Oli-Jay’s mother, Melanie Morris, expressed gratitude for the significant medications proposed in the report, emphasizing that while they are not a cure, they offer hope as a form of treatment.
The report highlighted that the current medication, midazolam, has a mere 3% effectiveness rate, whereas diazepam, with an 87% success rate, could be a more viable option for Oli-Jay. The young boy has been undergoing treatment at the NHS Addenbrooke’s Hospital in Cambridge for the past month due to respiratory complications.
Melanie has engaged with a range of medical professionals, including her son’s clinical team, the DNM1L Foundation, and staff at Addenbrooke’s, to delve into the report’s recommendations. While decisions are pending, discussions with specialists at Great Ormond Street Hospital are underway to formulate a tailored plan for Oli-Jay’s treatment.
Melanie remains hopeful, acknowledging the insights provided by the US medical team and the Foundation, which shed light on potential treatment avenues for Oli-Jay. She expressed optimism that understanding his needs better is a step towards ensuring his well-being, underscoring the Foundation’s pivotal role in their pursuit for a solution.
The family, supported by Oli-Jay’s older siblings, Jordon, Codi, and Tommy-Jay, has initiated a fundraising campaign on a GoFundMe page to secure funds for Oli’s treatment and ongoing care.
